Mamoru Hyodo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mamoru Hyodo has a total of 176 co-authors. Here are the top co-authors by number of shared publications:
Yoshihiro Hayakawa
Laboratory of Bioorganic Chemistry, Department of Applied Chemistry, Faculty of Engineering, Aichi Institute of Technology, Toyota, Japan, 470-0392
35 shared publicationsHideyoshi Harashima
Laboratory of Innovative Nanomedicine Faculty of Pharmaceutical Sciences Hokkaido University Kita 12, Nishi 6, Kita‐ku Sapporo Hokkaido 060‐0812 Japan
11 shared publicationsHidetaka Akita
Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita 12, Nishi 6, Kita-ku, Sapporo 060-0812, Japan
9 shared publications- Hideyoshi Harashima
Laboratory of Innovative Nanomedicine, Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12 Nishi-6, Kita-ku, Sapporo 060-0812, Japan
9 shared publications - Kazuaki Kajimoto
Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), 2217-14, Hayashi-cho, Takamatsu, Kagawa 761-0301, Japan
6 shared publications Kyoko Hida
Division of Vascular Biology Graduate School of Dental Medicine Hokkaido University Kita 13, Nishi 7, Kita‐ku Sapporo Hokkaido 060‐0812 Japan
6 shared publications
Latest Publications
- 18 July 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 624, 122034
Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody
- 18 July 2022
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 624, 122034
Interval- and cycle-dependent combined effect of STING agonist loaded lipid nanoparticles and a PD-1 antibody
- Open Access
- 1 January 2017
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 40 (7) , 1002-1009
Size-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 January 2017
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 40 (7) , 1002-1009
Open AccessSize-Dependency of the Surface Ligand Density of Liposomes Prepared by Post-insertion
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 March 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 225, 183-191
A lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
- 1 March 2016
- Published by Elsevier in Journal of Controlled Release
- Vol. 225, 183-191
Open AccessA lipid nanoparticle for the efficient delivery of siRNA to dendritic cells
- 5 June 2015
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 26 (7) , 1266-1276
Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System
A paradigm shift has occurred in the field of drug delivery systems (DDS), one being intracellular targeting, and the other, active targeting. An important aspect of intracellular targeting involves delivering nucleic acids such as siRNA/pDNA rather than small molecular compounds, since the mechanism responsible for their entering a target cell is usually via endocytosis, and the efficiency of endosomal escape is a critical factor in determining the functional activities of siRNA/pDNA. A multifunctional envelope-type nano device (MEND) was developed to control the intracellular trafficking of nano carriers containing siRNA/pDNA. An octaarginine (R8) modified MEND was developed to achieve this. Considerable progress has been made in active targeting to selective tissue vasculature such as tumor, adipose tissue, and the lung where endothelial barrier is tight against nanoparticles with diameters larger than 50 nm. A dual-ligand system is proposed to enhance active targeting ability by virtue of a synergistic interaction between a selective ligand and a cell penetrating ligand. Prohibitin targeted nanoparticles (PTNP) were developed to target endothelial cells in adipose tissue, which deliver apoptotic peptides/proteins to the adipose vasculature. Lung endothelial cells can be targeted by means of the GALA peptide, which is usually used to enhance endosomal escape. These active targeting systems can induce pharmacological effects in in vivo conditions. Finally, a novel strategy for producing an original ligand has been developed, especially for the tumor vasculature. This progress in DDS promises to extend the area of nanomedicine as a breakthrough technology.
- 5 June 2015
- Published by American Chemical Society (ACS) in Bioconjugate Chemistry
- Vol. 26 (7) , 1266-1276
Multifunctional Envelope-Type Nano Device: Evolution from Nonselective to Active Targeting System
A paradigm shift has occurred in the field of drug delivery systems (DDS), one being intracellular targeting, and the other, active targeting. An important aspect of intracellular targeting involves delivering nucleic acids such as siRNA/pDNA rather than small molecular compounds, since the mechanism responsible for their entering a target cell is usually via endocytosis, and the efficiency of endosomal escape is a critical factor in determining the functional activities of siRNA/pDNA. A multifunctional envelope-type nano device (MEND) was developed to control the intracellular trafficking of nano carriers containing siRNA/pDNA. An octaarginine (R8) modified MEND was developed to achieve this. Considerable progress has been made in active targeting to selective tissue vasculature such as tumor, adipose tissue, and the lung where endothelial barrier is tight against nanoparticles with diameters larger than 50 nm. A dual-ligand system is proposed to enhance active targeting ability by virtue of a synergistic interaction between a selective ligand and a cell penetrating ligand. Prohibitin targeted nanoparticles (PTNP) were developed to target endothelial cells in adipose tissue, which deliver apoptotic peptides/proteins to the adipose vasculature. Lung endothelial cells can be targeted by means of the GALA peptide, which is usually used to enhance endosomal escape. These active targeting systems can induce pharmacological effects in in vivo conditions. Finally, a novel strategy for producing an original ligand has been developed, especially for the tumor vasculature. This progress in DDS promises to extend the area of nanomedicine as a breakthrough technology.
- 1 June 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 184, 20-27
A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
- 1 June 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 184, 20-27
A new adjuvant delivery system ‘cyclic di-GMP/YSK05 liposome’ for cancer immunotherapy
- Open Access
- 9 May 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (4) , 825-834
Identification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand
The identification of a specific biomarker involves the development of new clinical diagnostic tools, and an in‐depth understanding of the disease at the molecular level. When new blood vessels form in tumor cells, endothelial cell production is induced, a process that plays a key role in disease progression and metastasis to distinct organs for solid tumor types. The present study reports on the identification of a new biomarker on primary cultured mouse tumor endothelial cells (mTECs) using our recently developed high‐affinity DNA aptamer AraHH001 (Kd = 43 nmol/L) assisted proteomics approach. We applied a strategy involving aptamer‐facilitated biomarker discovery. Biotin‐tagged AraHH001 was incubated with lysates of mTECs and the aptamer‐proteins were then conjugated with streptavidin magnetic beads. Finally, the bound proteins were separated by sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE) with silver staining. We identified troponin T via matrix assisted laser desorption ionization‐time of flight (MALDI‐TOF) mass spectrometry, the molecular target of aptamer AraHH001, and its presence was confirmed by measuring mRNA, protein levels, western blot, immunostaining, a gel shift assay of AraHH001 with troponin T. We first report here on the discovery of troponin T on mTECs, a promising and interesting diagnostic tool in the development of antiangiogenic therapy techniques the involves the targeting of the tumor vasculature.
- 9 May 2014
- Published by Wiley in Cancer Medicine
- Vol. 3 (4) , 825-834
Open AccessIdentification and expression of troponin T, a new marker on the surface of cultured tumor endothelial cells by aptamer ligand
The identification of a specific biomarker involves the development of new clinical diagnostic tools, and an in‐depth understanding of the disease at the molecular level. When new blood vessels form in tumor cells, endothelial cell production is induced, a process that plays a key role in disease progression and metastasis to distinct organs for solid tumor types. The present study reports on the identification of a new biomarker on primary cultured mouse tumor endothelial cells (mTECs) using our recently developed high‐affinity DNA aptamer AraHH001 (Kd = 43 nmol/L) assisted proteomics approach. We applied a strategy involving aptamer‐facilitated biomarker discovery. Biotin‐tagged AraHH001 was incubated with lysates of mTECs and the aptamer‐proteins were then conjugated with streptavidin magnetic beads. Finally, the bound proteins were separated by sodiumdodecyl sulfate polyacrylamide gel electrophoresis (SDS‐PAGE) with silver staining. We identified troponin T via matrix assisted laser desorption ionization‐time of flight (MALDI‐TOF) mass spectrometry, the molecular target of aptamer AraHH001, and its presence was confirmed by measuring mRNA, protein levels, western blot, immunostaining, a gel shift assay of AraHH001 with troponin T. We first report here on the discovery of troponin T on mTECs, a promising and interesting diagnostic tool in the development of antiangiogenic therapy techniques the involves the targeting of the tumor vasculature.
- 1 January 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 173, 110-118
RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system
- 1 January 2014
- Published by Elsevier in Journal of Controlled Release
- Vol. 173, 110-118
RNAi-mediated gene knockdown and anti-angiogenic therapy of RCCs using a cyclic RGD-modified liposomal-siRNA system
- 1 November 2013
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 116 (5) , 634-637
Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide
- 1 November 2013
- Published by Elsevier in Journal of Bioscience and Bioengineering
- Vol. 116 (5) , 634-637
Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide
- 1 October 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 171 (2) , 104-112
A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication
- 1 October 2013
- Published by Elsevier in Journal of Controlled Release
- Vol. 171 (2) , 104-112
A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medication
- 1 September 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (9) , 3119-3127
An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid
- 1 September 2013
- Published by Elsevier in Journal of Pharmaceutical Sciences
- Vol. 102 (9) , 3119-3127
An approach to transgene expression in liver endothelial cells using a liposome-based gene vector coated with hyaluronic acid